Ann: Positive IHL-675A in vivo results and FDA Pathway, page-61

The only worry I have is with Trump pushing HCQ and FDA being against it. If Camargo has FDA’s side and will see this thru nothing like it.

Considering the Mesoblast-Novartis deal last week was only for ARDS, IHL-675A has a wide range of applications to inflammation-linked diseases/ symptoms, I can only imagine how far are the pharma deals with or without FDA rubber stamping IHL-675A.

Below is just a glimpse of various diseases/ conditions which could benefit from our drug and hence the market/ deal potential.